Status:

TERMINATED

Validation of a Walk-Time Limit Test (WTLT) Derived from the 6-Minute Walk Test (6-MWT) in Patients with Chronic Cardiovascular or Respiratory Diseases

Lead Sponsor:

University Hospital, Brest

Conditions:

Chronic Obstructive Pulmonary Disease

Cardiovascular Insufficiency

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

Many exercise tests are commonly used to evaluate the changes of exercise tolerance following rehabilitation programs in patients with chronic respiratory diseases. Among the tests (6-MWT, incrementa...

Detailed Description

Each patient will perform 4 visits over a period of 4-week. Fifty subjects with COPD and fifty subjects with heart failure will be recruited for the same protocol. During the first visit, the subject...

Eligibility Criteria

Inclusion

  • Chronic Respiratory Disease Group:
  • Diagnosis of COPD with FEV1 corresponding to stages GOLD II or III (50-80% predicted or 30-50% predicted, respectively).
  • Patient's agreement
  • Being older than 18
  • Stable treatment for 3 months
  • Subjects affiliated with social security
  • Group cardiovascular diseases:
  • Diagnosis of heart failure or stable coronary artery disease with NYHA Class II stage.
  • Patient's agreement
  • Being older than 18
  • Stable treatment for 3 months
  • Subjects affiliated with social security

Exclusion

  • Any medical contraindications to the practice of a suitable physical activity
  • Presence of muscle, joint and / or neurological comorbidities affecting motor skills and test performance.
  • Refusal of the patient
  • Subject under guardianship or curatorship
  • Subject aged over 80 at the time of inclusion
  • Realization of a rehabilitation program during the study period
  • Subject under resting oxygen therapy
  • Diagnosis of heart failure, coronary artery disease or any cardiovascular pathology that required surgery.
  • Diagnosis of an associated chronic respiratory disease, such as asthma, pulmonary arterial hypertension or interstitial lung disease.

Key Trial Info

Start Date :

February 20 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 31 2024

Estimated Enrollment :

44 Patients enrolled

Trial Details

Trial ID

NCT04086953

Start Date

February 20 2020

End Date

January 31 2024

Last Update

March 28 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

CHRU Brest

Brest, France, France, 29200